SAN JOSE, Calif., March 17, 2023 (GLOBE NEWSWIRE) — Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the fourth quarter 2022 after market close on March 23, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights.
Interested parties may access the live call via telephone by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using conference ID: 2951533. The live webinar of the call may also be accessed by visiting the Events and Presentations section of Eargo’s website at ir.eargo.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Eargo’s website for one year.
About Eargo
Eargo is a medical device company on a mission to improve hearing health. Our innovative products and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost. We believe our Eargo hearing aids are the first virtually invisible, rechargeable, completely-in-canal, FDA-regulated devices indicated to compensate for mild to moderate hearing loss. Our differentiated, consumer-first approach empowers consumers to take control of their hearing. Consumers can purchase online, at retail locations or over the phone and get personalized and convenient consultation and support from hearing professionals via phone, text, email or video chat. Eargo hearing aids are offered to consumers at approximately half the cost of competing hearing aids purchased through traditional channels in the United States.
Eargo’s seventh generation device, Eargo 7, is an FDA 510(k) cleared, self-fitting over-the-counter hearing aid featuring Sound Adjust+ with Comfort and Clarity Modes, which focuses on noise reduction and adapting to the user’s environment and needs.
Related Links
http://eargo.com
Investor Contact
Nick Laudico
Chief Retail Officer
ir@eargo.com
Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Basal Cell Carcinoma…
Toronto, Ontario--(Newsfile Corp. - June 23, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…
Financials for Fiscal Year 2025 Ended March 31, 2025 will be released on Monday, June…
Company to also highlight advancements in denials and underpayments management and speak to the measurable…
Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility…
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…